Equity Profile

APLS

Apellis Pharmaceuticals, Inc.

Health CareBiotechnology$5.3B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, crucial for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

APLS Q2-2026 Earnings Preview

Context

Company Snapshot

Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. Operating in the health care sector, its work is particularly relevant as the demand for advanced medical treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+40.64%

Avg Stock Reaction

-4.40%

Last Quarter Recap

In Q1 2026, Apellis reported an EPS of $0.15, significantly beating expectations of a loss. However, the stock experienced a slight decline the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are anticipating strong performance from Apellis, especially following the positive surprise in the last quarter. However, uncertainty remains due to the lack of guidance.

Bull Case

If Apellis continues to outperform expectations, it could signal strong demand for its therapies and boost investor confidence.

Bear Case

Conversely, any signs of revenue stagnation or failure to meet even lowered expectations could lead to significant stock declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth will be crucial in assessing the company's market traction and overall health.

Will the company provide any guidance for future quarters?

Guidance can significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Apellis's ability to sustain its recent growth trajectory, especially given the strong EPS surprise last quarter.

Supporting Evidence

The company has a 75% EPS beat rate, indicating a strong track record of exceeding expectations.

Options pricing suggests a much larger move than historical averages, indicating heightened investor sentiment.

Key Risk

If revenue growth comes in below expectations, it could undermine the bullish narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued growth against the risks of disappointing results.

Bull Confirmed If

A revenue growth rate exceeding 20% would confirm the bullish outlook.

Bear Confirmed If

A revenue decline or stagnation would validate bearish concerns.

Pre-Earnings Positioning

Options Market

Implied Move

±34.35%

Historical Avg

±8.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±34.3% while APLS has averaged ±8.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

2.6%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 27 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 27 faded and 14 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.6%, with a raw directional average of +3.0% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Apellis beats expectations, history suggests the stock could see a modest increase, confirming positive market sentiment.

In-Line / Cautious

An in-line result may lead to a muted reaction, as investors await further clarity on future growth.

Miss

If the company misses expectations, the stock could drop significantly, as seen in past quarters.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Details on market demand for existing therapies.
3Insights into competitive pressures in the biotechnology sector.
4Management's outlook on regulatory approvals.
5Any commentary on cost management and operational efficiency.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Apellis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales, crucial for long-term sustainability.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

APLS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+40.64%

Avg Stock Reaction

-4.40%

Last Quarter Recap

In Q1 2026, Apellis reported an EPS of $0.15, significantly beating expectations of a loss. However, the stock experienced a slight decline the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are anticipating strong performance from Apellis, especially following the positive surprise in the last quarter. However, uncertainty remains due to the lack of guidance.

Bull Case

If Apellis continues to outperform expectations, it could signal strong demand for its therapies and boost investor confidence.

Bear Case

Conversely, any signs of revenue stagnation or failure to meet even lowered expectations could lead to significant stock declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for the upcoming quarter?

Revenue growth will be crucial in assessing the company's market traction and overall health.

Will the company provide any guidance for future quarters?

Guidance can significantly influence investor sentiment and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Apellis's ability to sustain its recent growth trajectory, especially given the strong EPS surprise last quarter.

Supporting Evidence

The company has a 75% EPS beat rate, indicating a strong track record of exceeding expectations.

Options pricing suggests a much larger move than historical averages, indicating heightened investor sentiment.

Key Risk

If revenue growth comes in below expectations, it could undermine the bullish narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued growth against the risks of disappointing results.

Bull Confirmed If

A revenue growth rate exceeding 20% would confirm the bullish outlook.

Bear Confirmed If

A revenue decline or stagnation would validate bearish concerns.

Pre-Earnings Positioning

Options Market

Implied Move

±34.35%

Historical Avg

±8.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±34.3% while APLS has averaged ±8.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

2.6%

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 27 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Apellis beats expectations, history suggests the stock could see a modest increase, confirming positive market sentiment.

In-Line / Cautious

An in-line result may lead to a muted reaction, as investors await further clarity on future growth.

Miss

If the company misses expectations, the stock could drop significantly, as seen in past quarters.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Details on market demand for existing therapies.
3Insights into competitive pressures in the biotechnology sector.
4Management's outlook on regulatory approvals.
5Any commentary on cost management and operational efficiency.